Erratum: Drug delivery nanoparticles in skin cancers (BioMed Research International (2014) 2014 (895986) DOI: 10.1155/2014/895986);Drug delivery nanoparticles in skin cancers

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Dianzani, Chiara ^a   Zara, Gian Paolo ^a   Maina, Giovanni ^a   Pettazzoni, Piergiorgio ^b   Pizzimenti, Stefania ^a   Rossi, Federica ^a   Gigliotti, Casimiro Luca ^c   Ciamporcero, Eric Stefano ^a   Daga, Martina ^a   Barrera, Giuseppina ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DENDRIMER; GOLD NANOPARTICLE; LIPOSOME; MESOPOROUS SILICA NANOPARTICLE; NANOCARRIER; NANOSPHERE; NANOTUBE; POLYMER; POLYMERIC MICELLE; QUANTUM DOT; SILICON DIOXIDE; SOLID LIPID NANOPARTICLE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; UNCLASSIFIED DRUG; DRUG CARRIER; NANOPARTICLE;

BASAL CELL CARCINOMA; CANCER CHEMOTHERAPY; CLINICAL TRIAL (TOPIC); DRUG DELIVERY SYSTEM; HUMAN; MELANOMA; NONMELANOMA SKIN CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SKIN CANCER; SQUAMOUS CELL CARCINOMA; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; PATHOLOGY; SKIN NEOPLASMS;

CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; MELANOMA; NANOPARTICLES; SKIN NEOPLASMS;

EID: 84904795730     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2021/6158298     Document Type: Erratum

References (154)

1. Singh R., Lillard J. W. Jr., Nanoparticle-based targeted drug delivery. Experimental and Molecular Pathology 2009 86 3 215 223 10.1016/j.yexmp.2008.12. 004 2-s2.0-67349179610
2. Bharali D. J., Khalil M., Gurbuz M., Simone T. M., Mousa S. A., Nanoparticles and cancer therapy: a concise review with emphasis on dendrimers. International Journal of Nanomedicine 2009 4 1 1 7 10.2217/17435889.4.1.1 2-s2.0-66149110011
3. Sanvicens N., Marco M. P., Multifunctional nanoparticles-properties and prospects for their use in human medicine. Trends in Biotechnology 2008 26 8 425 433 10.1016/j.tibtech.2008.04.005 2-s2.0-47049099053
4. Allen T. M., Cullis P. R., Drug Delivery Systems: Entering the Mainstream. Science 2004 303 5665 1818 1822 10.1126/science.1095833 2-s2.0-1642362625 (Pubitemid 38374867)
5. Emerich D. F., Thanos C. G., The pinpoint promise of nanoparticle-based drug delivery and molecular diagnosis. Biomolecular Engineering 2006 23 4 171 184 10.1016/j.bioeng.2006.05.026 2-s2.0-33746565966 (Pubitemid 44142336)
6. Jain R. K., Stylianopoulos T., Delivering nanomedicine to solid tumors. Nature Reviews Clinical Oncology 2010 7 11 653 664 10.1038/nrclinonc.2010.139 2-s2.0-78049452610
7. Jabr-Milane L. S., van Vlerken L. E., Yadav S., Amiji M. M., Multi-functional nanocarriers to overcome tumor drug resistance. Cancer Treatment Reviews 2008 34 7 592 602 10.1016/j.ctrv.2008.04.003 2-s2.0-53649089895
8. Misaka H., Zachariasb N., Songc Z., Hwangd S., Mana K. P., Asmatulua R., Yangb S. Y., Skin cancer treatment by albumin/5-Fu loaded magnetic nanocompositespheres in a mouse model. Journal of Biotechnology 2013 164 1 130 136
9. Jerant A. F., Johnson J. T., Sheridan C. D., Caffrey T. J., Early detection and treatment of skin cancer. American Family Physician 2000 62 2 357 382 2-s2.0-0034661340
10. Zhang L., Zhang N., How nanotechnology can enhance docetaxel therapy. International Journal of Nanomedicine 2013 8 1 2927 2941 10.2147/IJN.S46921 2-s2.0-84881307918
11. Torchilin V. P., Recent advances with liposomes as pharmaceutical carriers. Nature Reviews Drug Discovery 2005 4 2 145 160 10.1038/nrd1632 2-s2.0-14144250911 (Pubitemid 40282557)
12. Yuan F., Leunig M., Huang S. K., Berk D. A., Papahadjopoulos D., Jain R. K., Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Research 1994 54 13 3352 3356 2-s2.0-0028304405 (Pubitemid 24225946)
13. Slingerland M., Guchelaar H., Gelderblom H., Liposomal drug formulations in cancer therapy: 15 years along the road. Drug Discovery Today 2012 17 3-4 160 166 10.1016/j.drudis.2011.09.015 2-s2.0-84856452267
14. Yano J., Hirabayashi K., Nakagawa S., Yamaguchi T., Nogawa M., Kashimori I., Naito H., Kitagawa H., Ishiyama K., Ohgi T., Irimura T., Antitumor activity of small interfering RNA/cationic liposome complex in mouse models of cancer. Clinical Cancer Research 2004 10 22 7721 7726 10.1158/1078-0432.CCR-04-1049 2-s2.0-9344224580 (Pubitemid 39557537)
15. Muthu M. S., Feng S., Theranostic liposomes for cancer diagnosis and treatment: Current development and pre-clinical success. Expert Opinion on Drug Delivery 2013 10 2 151 155 10.1517/17425247.2013.729576 2-s2.0-84872744094
16. Soenen S. J. H., Cocquyt J., Defour L., Saveyn P., van der Meeren P., de Cuyper M., Design and development of magnetoliposome-based theranostics. Materials and Manufacturing Processes 2008 23 6 611 614 10.1080/ 10426910802160635 2-s2.0-47049094177
17. Huang S., Liposomes in ultrasonic drug and gene delivery. Advanced Drug Delivery Reviews 2008 60 10 1167 1176 10.1016/j.addr.2008.03.003 2-s2.0-44149127417
18. Mehnert W., Mäder K., Solid lipid nanoparticles: production, characterization and applications. Advanced Drug Delivery Reviews 2001 47 2-3 165 196 10.1016/S0169-409X(01)00105-3 2-s2.0-0035946615 (Pubitemid 32324113)
19. Mosallaei N., Jaafari M. R., Hanafi-Bojd M. Y., Golmohammadzadeh S., Malaekeh-Nikouei B., Docetaxel-loaded solid lipid nanoparticles: preparation, characterization, in vitro, and in vivo evaluations. Journal of Pharmaceutical Sciences 2013 102 6 1994 2004 10.1002/jps.23522 2-s2.0-84877925735
20. Minelli R., Serpe L., Pettazzoni P., Minero V., Barrera G., Gigliotti C. L., Mesturini R., Rosa A. C., Gasco P., Vivenza N., Muntoni E., Fantozzi R., Dianzani U., Zara G. P., Dianzani C., Cholesteryl butyrate solid lipid nanoparticles inhibit the adhesion and migration of colon cancer cells. British Journal of Pharmacology 2012 166 2 587 601 10.1111/j.1476-5381.2011.01768.x 2-s2.0-84859883485
21. Torchilin V. P., Micellar nanocarriers: pharmaceutical perspectives. Pharmaceutical Research 2007 24 1 1 16 10.1007/s11095-006-9132-0 2-s2.0-33845388144 (Pubitemid 44902565)
22. Fonseca M. J., Jagtenberg J. C., Haisma H. J., Storm G., Liposome-mediated targeting of enzymes to cancer cells for site-specific activation of prodrugs: comparison with the corresponding antibody-enzyme conjugate. Pharmaceutical Research 2003 20 3 423 428 10.1023/A:1022608321861 2-s2.0-0037338049 (Pubitemid 36288372)
23. Schnyder A., Krähenbühl S., Drewe J., Huwyler J., Targeting of daunomycin using biotinylated immunoliposomes: pharmacokinetics, tissue distribution and in vitro pharmacological effects. Journal of Drug Targeting 2005 13 5 325 335 10.1080/10611860500206674 2-s2.0-24644485229 (Pubitemid 41283166)
24. Farokhzad O. C., Cheng J., Teply B. A., Sherifi I., Jon S., Kantoff P. W., Richie J. P., Langer R., Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proceedings of the National Academy of Sciences of the United States of America 2006 103 16 6315 6320 10.1073/pnas.0601755103 2-s2.0-33646582037
25. Zhang L., Radovic-Moreno A. F., Alexis F., Gu F. X., Basto P. A., Bagalkot V., Jon S., Langer R. S., Farokhzad O. C., Co-delivery of hydrophobic and hydrophilic drugsfrom nanoparticle-aptamer bioconjugates. ChemMedChem 2007 2 9 1268 1271 10.1002/cmdc.200700121 2-s2.0-42349106952
26. Zhang L., Gu F. X., Chan J. M., Wang A. Z., Langer R. S., Farokhzad O. C., Nanoparticles in medicine: therapeutic applications and developments. Clinical Pharmacology and Therapeutics 2008 83 5 761 769 10.1038/sj.clpt.6100400 2-s2.0-42349094203 (Pubitemid 351556021)
27. Coimbra M., Rijcken C. J. F., Stigter M., Hennink W. E., Storm G., Schiffelers R. M., Antitumor efficacy of dexamethasone-loaded core-crosslinked polymeric micelles. Journal of Controlled Release 2012 163 3 361 367 10.1016/j.jconrel.2012.09.014 2-s2.0-84867590972
28. Nazir S., Hussain T., Ayub A., Rashid U., Macrobert A. J., Nanomaterials in combating cancer: therapeutic applications and developments. Nanomedicine 2013 10 1 19 34 10.1016/j.nano.2013.07.001
29. Paleos C. M., Tsiourvas D., Sideratou Z., Tziveleka L., Drug delivery using multifunctional dendrimers and hyperbranched polymers. Expert Opinion on Drug Delivery 2010 7 12 1387 1398 10.1517/17425247.2010.534981 2-s2.0-78649960950
30. Svenson S., Dendrimers as versatile platform in drug delivery applications. European Journal of Pharmaceutics and Biopharmaceutics 2009 71 3 445 462 10.1016/j.ejpb.2008.09.023 2-s2.0-60749099362
31. Jaracz S., Chen J., Kuznetsova L. V., Ojima I., Recent advances in tumor-targeting anticancer drug conjugates. Bioorganic and Medicinal Chemistry 2005 13 17 5043 5054 10.1016/j.bmc.2005.04.084 2-s2.0-22844436226 (Pubitemid 41039965)
32. Kojima C., Kono K., Maruyama K., Takagishi T., Synthesis of polyamidoamine dendrimers having poly(ethylene glycol) grafts and their ability to encapsulate anticancer drugs. Bioconjugate Chemistry 2000 11 6 910 917 10.1021/bc0000583 2-s2.0-0033657796
33. Larocque J., Bharali D. J., Mousa S. A., Cancer detection and treatment: The role of nanomedicines. Molecular Biotechnology 2009 42 3 358 366 10.1007/s12033-009-9161-0 2-s2.0-70349325793
34. Chen J., Shao R., Zhang X. D., Chen C., Applications of nanotechnology for melanoma treatment, diagnosis, and theranostics. International Journal of Nanomedicine 2013 8 1 2677 2688 10.2147/IJN.S45429 2-s2.0-84880754766
35. Battah S., Balaratnam S., Casas A., O'Neill S., Edwards C., Batlle A., Dobbin P., MacRobert A. J., Macromolecular delivery of 5-aminolaevulinic acid for photodynamic therapy using dendrimer conjugates. Molecular Cancer Therapeutics 2007 6 3 876 885 10.1158/1535-7163.MCT-06-0359 2-s2.0-34147159744 (Pubitemid 46554557)
36. Kobayashi H., Brechbiel M. W., Dendrimer-based macromolecular MRI contrast agents: characteristics and application. Molecular Imaging 2003 2 1 1 10 10.1162/153535003765276237 2-s2.0-0041472781
37. Polizu S., Savadogo O., Poulin P., Yahia L., Applications of carbon nanotubes-based biomaterials in biomedical nanotechnology. Journal of Nanoscience and Nanotechnology 2006 6 7 1883 1904 10.1166/jnn.2006.197 2-s2.0-33750159066 (Pubitemid 44599074)
38. McDevitt M. R., Chattopadhyay D., Kappel B. J., Jaggi J. S., Schiffman S. R., Antczak C., Njardarson J. T., Brentjens R., Scheinberg D. A., Tumor targeting with antibody-functionalized, radiolabeled carbon nanotubes. Journal of Nuclear Medicine 2007 48 7 1180 1189 10.2967/jnumed.106.039131 2-s2.0-34447329851 (Pubitemid 47052659)
39. Bosi S., da Ros T., Spalluto G., Prato M., Fullerene derivatives: an attractive tool for biological applications. European Journal of Medicinal Chemistry 2003 38 11-12 913 923 10.1016/j.ejmech.2003.09.005 2-s2.0-0345257786 (Pubitemid 37455402)
40. Naderi N., Madani S. Y., Ferguson E., Mosahebi A., Seifalian A. M., Carbon nanotubes in the diagnosis and treatment of malignant melanoma. Anti-Cancer Agents in Medicinal Chemistry 2013 13 1 171 185 10.2174/ 187152013804487335 2-s2.0-84880161536
41. Slowing I. I., Trewyn B. G., Giri S., Lin V. S. Y., Mesoporous silica nanoparticles for drug delivery and biosensing applications. Advanced Functional Materials 2007 17 8 1225 1236 10.1002/adfm.200601191 2-s2.0-34249780352 (Pubitemid 46847636)
42. Slowing I. I., Vivero-Escoto J. L., Wu C. W., Lin V. S. Y., Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Advanced Drug Delivery Reviews 2008 60 11 1278 1288 10.1016/j.addr.2008.03.012 2-s2.0-46749123819
43. Torney F., Trewyn B. G., Lin V. S.-., Wang K., Mesoporous silica nanoparticles deliver DNA and chemicals into plants. Nature Nanotechnology 2007 2 5 295 300 10.1038/nnano.2007.108 2-s2.0-34250001748 (Pubitemid 46882970)
44. Slowing I., Trewyn B. G., Lin V. S. Y., Effect of surface functionalization of MCM-41-type mesoporous silica. Journal of the American Chemical Society 2006 128 46 14792 14793 10.1021/ja0645943 2-s2.0-33845231619 (Pubitemid 44851603)
45. Cauda V., Schlossbauer A., Kecht J., Zürner A., Bein T., Multiple core-shell functionalized colloidal mesoporous silica nanoparticles. Journal of the American Chemical Society 2009 131 32 11361 11370 10.1021/ja809346n 2-s2.0-68849094987
46. Tsai C., Chen C., Hung Y., Chang F., Mou C., Monoclonal antibody-functionalized mesoporous silica nanoparticles (MSN) for selective targeting breast cancer cells. Journal of Materials Chemistry 2009 19 32 5737 5743 10.1039/b905158a 2-s2.0-68349141561
47. Wang Y., Chen L., Quantum dots, lighting up the research and development of nanomedicine. Nanomedicine: Nanotechnology, Biology, and Medicine 2011 7 4 385 402 10.1016/j.nano.2010.12.006 2-s2.0-79960732446
48. Alivisatos A. P., Semiconductor clusters, nanocrystals, and quantum dots. Science 1996 271 5251 933 937 10.1126/science.271.5251.933 2-s2.0-0030084093 (Pubitemid 126554899)
49. Huang H., Barua S., Sharma G., Dey S. K., Rege K., Inorganic nanoparticles for cancer imaging and therapy. Journal of Controlled Release 2011 155 3 344 357 10.1016/j.jconrel.2011.06.004 2-s2.0-80054689368
50. Medintz I. L., Uyeda H. T., Goldman E. R., Mattoussi H., Quantum dot bioconjugates for imaging, labelling and sensing. Nature Materials 2005 4 6 435 446 10.1038/nmat1390 2-s2.0-20144379798 (Pubitemid 40774047)
51. Ruoslahti E., Bhatia S. N., Sailor M. J., Targeting of drugs and nanoparticles to tumors. Journal of Cell Biology 2010 188 6 759 768 10.1083/jcb.200910104 2-s2.0-77949762340
52. Ji T., Zhao Y., Ding Y., Nie G., Using functional nanomaterials to target and regulate the tumor microenvironment: Diagnostic and therapeutic applications. Advanced Materials 2013 25 26 3508 3525 10.1002/adma.201300299 2-s2.0-84879977345
53. Johannsen M., Gneveckow U., Taymoorian K., Thiesen B., Waldöfner N., Scholz R., Jung K., Jordan A., Wust P., Loening S. A., Morbidity and quality of life during thermotherapy using magnetic nanoparticles in locally recurrent prostate cancer: results of a prospective phase I trial. International Journal of Hyperthermia 2007 23 3 315 323 10.1080/02656730601175479 2-s2.0-34249858538 (Pubitemid 46860598)
54. Kievit F. M., Zhang M., Surface engineering of iron oxide nanoparticles for targeted cancer therapy. Accounts of Chemical Research 2011 44 10 853 862 10.1021/ar2000277 2-s2.0-80054769977
55. Wang Y. X., Wang D. W., Zhu X. M., Zhao F., Leung K. C., Carbon coated superparamagnetic iron oxide nanoparticles for sentinel lymph nodes mapping. Quantitative Imaging in Medicine and Surgery 2012 2 1 53 56
56. Zavaleta C. L., Smith B. R., Walton I., Doering W., Davis G., Shojaei B., Natan M. J., Gambhir S. S., Multiplexed imaging of surface enhanced Ramanscattering nanotags in living mice using noninvasive Raman spectroscopy. Proceedings of the National Academy of Sciences of the United States of America 2009 106 32 13511 13516
57. Lu W., Huang Q., Ku G., Wen X., Zhou M., Guzatov D., Brecht P., Su R., Oraevsky A., Wang L. V., Li C., Photoacoustic imaging of living mouse brain vasculature using hollow gold nanospheres. Biomaterials 2010 31 9 2617 2626 10.1016/j.biomaterials.2009.12.007 2-s2.0-74449093082
58. Albrecht R., Immunocytochemistry: A Practical Approach 1993 2 chapter 7 Oxford, UK Oxford University Press. Edited by E. J. Beesley
59. Sonavane G., Tomoda K., Makino K., Biodistribution of colloidal gold nanoparticles after intravenous administration: effect of particle size. Colloids and Surfaces B: Biointerfaces 2008 66 2 274 280 10.1016/j.colsurfb. 2008.07.004 2-s2.0-50649113474
60. Dreaden E. C., Austin L. A., MacKey M. A., El-Sayed M. A., Size matters: Gold nanoparticles in targeted cancer drug delivery. Therapeutic Delivery 2012 3 4 457 478 10.4155/tde.12.21 2-s2.0-84859252945
61. Qian X., Peng X., Ansari D. O., Yin-Goen Q., Chen G. Z., Shin D. M., Yang L., Young A. N., Wang M. D., Nie S., In vivo tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags. Nature Biotechnology 2008 26 1 83 90 10.1038/nbt1377 2-s2.0-38049047244
62. Jokerst J. V., Gambhir S. S., Molecular imaging with theranostic nanoparticles. Accounts of Chemical Research 2011 44 10 1050 1060 10.1021/ar200106e 2-s2.0-80054745992
63. Huang X., Jain P. K., El-Sayed I. H., El-Sayed M. A., Gold nanoparticles: Interesting optical properties and recent applications in cancer diagnostics and therapy. Nanomedicine 2007 2 5 681 693 10.2217/17435889.2.5.681 2-s2.0-37249089714 (Pubitemid 350268247)
64. Kimling J., Maier M., Okenve B., Kotaidis V., Ballot H., Plech A., Turkevich method for gold nanoparticle synthesis revisited. Journal of Physical Chemistry B 2006 110 32 15700 15707 10.1021/jp061667w 2-s2.0-33748547223 (Pubitemid 44366341)
65. Hainfeld J. F., Dilmanian F. A., Slatkin D. N., Smilowitz H. M., Radiotherapy enhancement with gold nanoparticles. Journal of Pharmacy and Pharmacology 2008 60 8 977 985 10.1211/jpp.60.8.0005 2-s2.0-47949117043
66. Pan Y., Neuss S., Leifert A., Fischler M., Wen F., Simon U., Schmid G., Brandau W., Jahnen-Dechent W., Size-dependent cytotoxicity of gold nanoparticles. Small 2007 3 11 1941 1949 10.1002/smll.200700378 2-s2.0-36049015878 (Pubitemid 350099867)
67. Prow T. W., Grice J. E., Lin L. L., Faye R., Butler M., Becker W., Wurm E. M. T., Yoong C., Robertson T. A., Soyer H. P., Roberts M. S., Nanoparticles and microparticles for skin drug delivery. Advanced Drug Delivery Reviews 2011 63 6 470 491 10.1016/j.addr.2011.01.012 2-s2.0-79953198946
68. Delouise L. A., Applications of nanotechnology in dermatology. Journal of Investigative Dermatology 2012 132 3 964 975 10.1038/jid.2011.425 2-s2.0-84857053855
69. Taveira S. F., Vianna Lopez R. F., La Porta C., Topical administration of anticancer drugs for skin cancer treatment. Topical Administration of Anticancer Drugs for Skin Cancer Treatment 2011 247 272
70. Weiss M. B., Andrew E., Aplin A. E., Paying particle attention to novel melanoma treatment strategies. Journal of Investigation Dermatology 2010 130 2699 2701
71. Souza J. G., Gelfuso G. M., Simão P. S., Borges A. C., Lopez R. F. V., Iontophoretic transport of zinc phthalocyanine tetrasulfonic acid as a tool to improve drug topical delivery. Anti-Cancer Drugs 2011 22 8 783 793 10.1097/CAD.0b013e3283468979 2-s2.0-80051552549
72. Williams A. C., Barry B. W., Penetration enhancers. Advanced Drug Delivery Reviews 2004 56 5 603 618 10.1016/j.addr.2003.10.025 2-s2.0-1542298898 (Pubitemid 38326936)
73. Barrera M. V., Herrera E., Topical chemotherapy for actinic keratosis and nonmelanoma skin cancer: current options and future perspectives. Actas Dermo-Sifiliográficas 2007 98 8 556 562 10.1016/S0001-7310(07)70133-3 2-s2.0-35349012586 (Pubitemid 47596711)
74. Galiczynski E. M., Vidimos A. T., Nonsurgical treatment of nonmelanoma skin cancer. Dermatologic Clinics 2011 29 2 297 309 10.1016/j.det.2011.01.011 2-s2.0-79952748672
75. Schmid M.-., Korting H. C., Therapeutic progress with topical liposome drugs for skin disease. Advanced Drug Delivery Reviews 1996 18 3 335 342 10.1016/0169-409X(95)00019-4 2-s2.0-0030574684 (Pubitemid 26063307)
76. Gratieri T., Gelfuso G. M., Lopez R. F., Souto E. B., Current efforts and the potential of nanomedicine in treating fungal keratitis. Expert Review of Ophthalmology 2010 5 3 365 384 10.1586/eop.10.19 2-s2.0-77953225102
77. Hosoda J., Unezaki S., Maruyama K., Tsuchiya S., Iwatsuru M., Antitumor activity of doxorubicin encapsulated in poly(ethylene glycol)-coated liposomes. Biological and Pharmaceutical Bulletin 1995 18 9 1234 1237 10.1248/bpb.18.1234 2-s2.0-0029095214
78. Barenholz Y., Liposome application: problems and prospects. Current Opinion in Colloid & Interface Science 2001 6 1 66 77 10.1016/S1359-0294(00) 00090-X 2-s2.0-0035085192 (Pubitemid 32233069)
79. Lasic D., Huang L., Hung M. C., Wagner E., Structure and structure-activity relationships of lipid-based gene delivery systems. Nonviral Vectors for Gene Therapy 1999 San Diego, Calif, USA Academic Press 69 89
80. Krieger M. L., Eckstein N., Schneider V., Koch M., Royer H., Jaehde U., Bendas G., Overcoming cisplatin resistance of ovarian cancer cells by targeted liposomes in vitro. International Journal of Pharmaceutics 2010 389 1-2 10 17 10.1016/j.ijpharm.2009.12.061 2-s2.0-77349118427
81. Abu Lila A. S., Doi Y., Nakamura K., Ishida T., Kiwada H., Sequential administration with oxaliplatin-containing PEG-coated cationic liposomes promotes a significant delivery of subsequent dose into murine solid tumor. Journal of Controlled Release 2010 142 2 167 173 10.1016/j.jconrel.2009.10.020 2-s2.0-76749093024
82. Watanabe M., Kawano K., Toma K., Hattori Y., Maitani Y., In vivo antitumor activity of camptothecin incorporated in liposomes formulated with an artificial lipid and human serum albumin. Journal of Controlled Release 2008 127 3 231 238 10.1016/j.jconrel.2008.02.005 2-s2.0-42049093001
83. Fang Y., Tsai Y., Wu P., Huang Y., Comparison of 5-aminolevulinic acid-encapsulated liposome versus ethosome for skin delivery for photodynamic therapy. International Journal of Pharmaceutics 2008 356 1-2 144 152 10.1016/j.ijpharm.2008.01.020 2-s2.0-42649086013
84. Oh E. K., Jin S. E., Kim J. K., Park J., Park Y., Kim C., Retained topical delivery of 5-aminolevulinic acid using cationic ultradeformable liposomes for photodynamic therapy. European Journal of Pharmaceutical Sciences 2011 44 1-2 149 157 10.1016/j.ejps.2011.07.003 2-s2.0-80052037845
85. Pierre M. B., Ricci E. Jr., Tedesco A. C., Bentley M. V., Oleic acid as optimizer of the skin delivery of 5-aminolevulinic acid in photodynamic therapy. Pharmaceutical Research 2006 23 2 360 366 10.1007/s11095-005-9261-x 2-s2.0-32544439698 (Pubitemid 43237865)
86. Paolino D., Cosco D., Muzzalupo R., Trapasso E., Picci N., Fresta M., Innovative bola-surfactant niosomes as topical delivery systems of 5-fluorouracil for the treatment of skin cancer. International Journal of Pharmaceutics 2008 353 1-2 233 242 10.1016/j.ijpharm.2007.11.037 2-s2.0-40149107853
87. Kitagawa S., Kasamaki M., Enhanced delivery of retinoic acid to skin by cationic liposomes. Chemical and Pharmaceutical Bulletin 2006 54 2 242 244 10.2322/jjsass.54.242 2-s2.0-32044464779 (Pubitemid 43200608)
88. Zaafarany G. M. E., Awad G. A. S., Holayel S. M., Mortada N. D., Role of edge activators and surface charge in developing ultradeformable vesicles with enhanced skin delivery. International Journal of Pharmaceutics 2010 397 1-2 164 172 10.1016/j.ijpharm.2010.06.034 2-s2.0-77955980602
89. Glavas-Dodov M., Fredro-Kumbaradzi E., Goracinova K., Simonoska M., Calis S., Trajkovic-Jolevska S., Hincal A. A., The effects of lyophilization on the stability of liposomes containing 5-FU. International Journal of Pharmaceutics 2005 291 1-2 79 86 10.1016/j.ijpharm.2004.07.045 2-s2.0-13544266376 (Pubitemid 40221999)
90. Rancan F., Papakostas D., Hadam S., Hackbarth S., Delair T., Primard C., Verrier B., Sterry W., Blume-Peytavi U., Vogt A., Investigation of polylactic acid (PLA) nanoparticles as drug delivery systems for local dermatotherapy. Pharmaceutical Research 2009 26 8 2027 2036 10.1007/s11095-009-9919-x 2-s2.0-67650064830
91. Teixeira Z., Zanchetta B., Melo B., Oliveira L. L., Santana M. H. A., Paredes-Gamero E. J., Justo G. Z., Nader H. B., Guterres S. S., Durán N., Retinyl palmitate flexible polymeric nanocapsules: characterization and permeation studies. Colloids and Surfaces B: Biointerfaces 2010 81 1 374 380 10.1016/j.colsurfb.2010.06.016 2-s2.0-77956012646
92. Marquele-Oliveira F., de Almeida Santana D. C., Taveira S. F., Vermeulen D. M., Moraes de Oliveira A. R., da Silva R. S., Lopez R. F. V., Development of nitrosyl ruthenium complex-loaded lipid carriers for topical administration: improvement in skin stability and in nitric oxide release by visible light irradiation. Journal of Pharmaceutical and Biomedical Analysis 2010 53 4 843 851 10.1016/j.jpba.2010.06.007 2-s2.0-77955586012
93. Misak H., Zacharias N., Song Z., Hwang S., Man K.-., Asmatulu R., Yang S.-., Skin cancer treatment by albumin/5-Fu loaded magnetic nanocomposite spheres in a mouse model. Journal of Biotechnology 2013 164 1 130 136 10.1016/j.jbiotec.2013.01.003 2-s2.0-84875092259
94. Joseph M. G., Zulueta W. P., Kennedy P. J., Squamous cell carcinoma of the skin of the trunk and limbs: the incidence of metastases and their outcome. The Australian and New Zealand Journal of Surgery 1992 62 9 697 701 10.1111/j.1445-2197.1992.tb07065.x 2-s2.0-0026670718
95. Wadhera A., Fazio M., Bricca G., Stanton O., Metastatic basal cell carcinoma: a case report and literature review. How accurate is our incidence data? Dermatology Online Journal 2006 12 5, article 7 2-s2.0-33749169664
96. Sturm H. M., Bowen's disease and 5-fluorouracil. Journal of the American Academy of Dermatology 1979 1 6 513 522 10.1016/S0190-9622(79)80095-X 2-s2.0-0018586248
97. Mandekou-Lefaki I., Delli F., Koussidou-Eremondi T., Mourellou-Tsatsou O., Dionyssopoulos A., Imiquimod 5% cream: a new treatment for Bowen's disease. International Journal of Tissue Reactions 2005 27 1 31 38 2-s2.0-15944371467 (Pubitemid 40439617)
98. Goette D. K., Topical chemotherapy with 5-fluorouracil. Journal of the American Academy of Dermatology 1981 4 6 633 649 10.1016/S0190-9622(81)80196-X 2-s2.0-0019826126
99. Hadjikirova M., Troyanova P., Simeonova M., Nanoparticles as drug carrier system of 5-fluorouracil in local treatment of patients with superficial basal cell carcinoma. Journal of BUON 2005 10 4 517 521 2-s2.0-33344466869 (Pubitemid 43285557)
100. Huang Z., Xu H., Meyers A. D., Musani A. I., Wang L., Tagg R., Barqawi A. B., Chen Y. K., Photodynamic therapy for treatment of solid tumors-potential and technical challenges. Technology in Cancer Research and Treatment 2008 7 4 309 320 2-s2.0-50249098813
101. Morton C. A., Szeimies R. M., Sidoroff A., Braathen L. R., European guidelines for topical photodynamic therapy-part 1: treatment delivery and current indications-actinic keratoses, Bowen's disease, basal cell carcinoma. Journal of the European Academy of Dermatology and Venereology 2013 27 5 536 544 10.1111/jdv.12031 2-s2.0-84876143115
102. Morton C. A., McKenna K. E., Rhodes L. E., Guidelines for topical photodynamic therapy: update. British Journal of Dermatology 2008 159 6 1245 1266 10.1111/j.1365-2133.2008.08882.x 2-s2.0-56549129972
103. Casas A., Batlle A., Aminolevulinic acid derivatives and liposome delivery as strategies for improving 5-aminolevulinic acid- mediated photodynamic therapy. Current Medicinal Chemistry 2006 13 10 1157 1168 10.2174/092986706776360888 2-s2.0-33645996061
104. Yang S., Shieh M., Lin F., Lou P., Peng C., Wei M., Yao C., Lai P., Young T., Colorectal cancer cell detection by 5-aminolaevulinic acid-loaded chitosan nano-particles. Cancer Letters 2009 273 2 210 220 10.1016/j.canlet.2008.08.014 2-s2.0-57349199717
105. Yang S. J., Lin C. F., Kuo M. L., Tan C. T., Photodynamic detection of oral cancers with high-performance chitosan-based nanoparticles. Biomacromolecules 2013 14 9 3183 3191 10.1021/bm400820s
106. Shi L., Wang X., Zhao F., Luan H., Tu Q., Huang Z., Wang H., In vitro evaluation of 5-aminolevulinic acid (ALA) loaded PLGA nanoparticles. International Journal of Nanomedicine 2013 8 1 2669 2676 10.2147/IJN.S45821 2-s2.0-84880758800
107. Rejiya C. S., Kumar J., Raji V., Vibin M., Abraham A., Laser immunotherapy with gold nanorods causes selective killing of tumour cells. Pharmacological Research 2012 65 2 261 269 10.1016/j.phrs.2011.10.005 2-s2.0-84855989939
108. Das S., Das J., Samadder A., Paul A., Khuda-Bukhsh A. R., Efficacy of PLGA-loaded apigenin nanoparticles in Benzo[a]pyrene and ultraviolet-B induced skin cancer of mice: Mitochondria mediated apoptotic signalling cascades. Food and Chemical Toxicology 2013 62 670 680
109. Wei H., Tye L., Bresnick E., Birt D. F., Inhibitory effect of apigenin, a plant flavonoid, on epidermal ornithine decarboxylase and skin tumor promotion in mice. Cancer Research 1990 50 3 499 502 2-s2.0-0025176844 (Pubitemid 20054168)
110. Birt D. F., Mitchell D., Gold B., Pour P., Pinch H. C., Inhibition of ultraviolet light induced skill carcinogenesis in SKH-1 mice by apigenin, a plant flavonoid. Anticancer Research 1997 17 1A 85 91 2-s2.0-0031057115 (Pubitemid 27116649)
111. Pfeiffer P., Hansen O., Rose C., Systemic cytotoxic therapy of basal cell carcinoma. A review of the literature. European Journal of Cancer 1990 26 1 73 77 10.1016/0277-5379(90)90262-R 2-s2.0-0025266161 (Pubitemid 20121854)
112. Hahn H., Wicking C., Zaphiropoulos P. G., Christiansen J., Chidambaram A., Gerrard B., Vorechovsky I., Bale A. E., Toftgard R., Dean M., Wainwright B., A mammalian patched homolog is expressed in target tissues of sonic hedgehog and maps to a region associated with developmental abnormalities. Journal of Biological Chemistry 1996 271 21 12125 12128 10.1074/jbc.271.21.12125 2-s2.0-15844382075 (Pubitemid 26160866)
113. Iwasaki J. K., Srivastava D., Moy R. L., Lin H. J., Kouba D. J., The molecular genetics underlying basal cell carcinoma pathogenesis and links to targeted therapeutics. Journal of the American Academy of Dermatology 2012 66 5 e167 e178 10.1016/j.jaad.2010.06.054 2-s2.0-84859847132
114. Xu Y., Chenna V., Hu C., Sun H., Khan M., Bai H., Yang X., Zhu Q., Sun Y., Maitra A., Fan J., Anders R. A., Polymeric nanoparticle-encapsulated hedgehog pathway inhibitor HPI-1 (NanoHHI) inhibits systemic metastases in an orthotopic model of human hepatocellular carcinoma. Clinical Cancer Research 2012 18 5 1291 1302 10.1158/1078-0432.CCR-11-0950 2-s2.0-84863264746
115. Eigentler T. K., Caroli U. M., Radny P., Garbe C., Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. The Lancet Oncology 2003 4 12 748 759 10.1016/S1470-2045(03)01280-4 2-s2.0-0347503603 (Pubitemid 37527210)
116. Falkson C. I., Ibrahim J., Kirkwood J. M., Coates A. S., Atkins M. B., Blum R. H., Phase III trial of dacarbazine versus dacarbazine with interferon α -2b versus dacarbazine with tamoxifen versus dacarbazine with interferon α -2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative oncology Group Study. Journal of Clinical Oncology 1998 16 5 1743 1751 2-s2.0-0031805725
117. Atkins M. B., Hsu J., Lee S., Cohen G. I., Flaherty L. E., Sosman J. A., Sondak V. K., Kirkwood J. M., Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. Journal of Clinical Oncology 2008 26 35 5748 5754 10.1200/JCO.2008.17.5448 2-s2.0-53949108399
118. Sharma A., Sharma A. K., Madhunapantula S. V., Desai D., Huh S. J., Mosca P., Amin S., Robertson G. P., Targeting Akt3 signaling in malignant melanoma using isoselenocyanates. Clinical Cancer Research 2009 15 5 1674 1685 10.1158/1078-0432.CCR-08-2214 2-s2.0-63449115826
119. Tran M. A., Watts R. J., Robertson G. P., Use of liposomes as drug delivery vehicles for treatment of melanoma. Pigment Cell and Melanoma Research 2009 22 4 388 399 10.1111/j.1755-148X.2009.00581.x 2-s2.0-67749135874
120. Bei D., Meng J., Youan B. C., Engineering nanomedicines for improved melanoma therapy: progress and promises. Nanomedicine 2010 5 9 1385 1399 10.2217/nnm.10.117 2-s2.0-78650068229
121. Pacheco I., Buzea C., Tron V., Towards new therapeutic approaches for malignant melanoma. Expert Reviews in Molecular Medicine 2011 13 e33 10.1017/S146239941100202X 2-s2.0-84857093928
122. Zhang X., Chibli H., Kong D., Nadeau J., Comparative cytotoxicity of gold-doxorubicin and InP-doxorubicin conjugates. Nanotechnology 2012 23 27 275103 10.1088/0957-4484/23/27/275103 2-s2.0-84862686741
123. lo Prete A. C., Maria D. A., Rodrigues D. G., Valduga C. J., Ibañez O. C., Maranhão R. C., Evaluation in melanoma-bearing mice of an etoposide derivative associated to a cholesterol-rich nanoemulsion. Journal of Pharmacy and Pharmacology 2006 58 6 801 808 10.1211/jpp.58.6.0010 2-s2.0-33744814347 (Pubitemid 43836166)
124. Ndinguri M. W., Zheleznyak A., Lauer J. L., Anderson C. J., Fields G. B., Application of collagen-model triple-helical peptide-amphiphiles for CD44-targeted drug delivery systems. Journal of Drug Delivery 2012 2012 13 592602 10.1155/2012/592602
125. Hersh E. M., O'Day S. J., Ribas A., Samlowski W. E., Gordon M. S., Shechter D. E., Clawson A. A., Gonzalez R., A phase 2 clinical trial of nab-Paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma. Cancer 2010 116 1 155 163 10.1002/cncr.24720 2-s2.0-74549221384
126. Kottschade L. A., Suman V. J., Amatruda T. III, McWilliams R. R., Mattar B. I., Nikcevich D. A., Behrens R., Fitch T. R., Jaslowski A. J., Markovic S. N., A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma. Cancer 2011 117 8 1704 1710 10.1002/cncr.25659 2-s2.0-79953798396
127. Kottschade L. A., Suman V. J., Perez D. G., McWilliams R. R., Kaur J. S., Amatruda T. T. III, Geoffroy F. J., Gross H. M., Cohen P. A., Jaslowski A. J., Kosel M. L., Markovic S. N., A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma: a north central cancer treatment group study, N0775. Cancer 2013 119 3 586 592 10.1002/cncr.27760 2-s2.0-84872956413
128. Ott P. A., Chang J., Madden K., Kannan R., Muren C., Escano C., Cheng X., Shao Y., Mendoza S., Gandhi A., Liebes L., Pavlick A. C., Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial. Cancer Chemotherapy and Pharmacology 2013 71 1 183 191 10.1007/s00280-012-1995-7 2-s2.0-84872287502
129. Hwang T., Lee W., Hua S., Fang J., Cisplatin encapsulated in phosphatidylethanolamine liposomes enhances the in vitro cytotoxicity and in vivo intratumor drug accumulation against melanomas. Journal of Dermatological Science 2007 46 1 11 20 10.1016/j.jdermsci.2006.12.011 2-s2.0-33847769265 (Pubitemid 46389476)
130. Mitrus I., Sochanik A., Cichoń T., Szala S., Combination of combretastatin A4 phosphate and doxorubicin-containing liposomes affects growth of B16-F10 tumors. Acta Biochimica Polonica 2009 56 1 161 165 2-s2.0-67249095624
131. Banciu M., Metselaar J. M., Schiffelers R. M., Storm G., Liposomal glucocorticoids as tumor-targeted anti-angiogenic nanomedicine in B16 melanoma-bearing mice. The Journal of Steroid Biochemistry and Molecular Biology 2008 111 1-2 101 110 10.1016/j.jsbmb.2008.05.004 2-s2.0-47849109307
132. Banciu M., Schiffelers R. M., Fens M. H. A. M., Metselaar J. M., Storm G., Anti-angiogenic effects of liposomal prednisolone phosphate on B16 melanoma in mice. The Journal of Controlled Release 2006 113 1 1 8 10.1016/j.jconrel. 2006.03.019 2-s2.0-33744509034 (Pubitemid 43818165)
133. Tran M. A., Watts R. J., Robertson G. P., Use of liposomes as drug delivery vehicles for treatment of melanoma. Pigment Cell & Melanoma Research 2009 22 4 388 399 10.1111/j.1755-148X.2009.00581.x 2-s2.0-67749135874
134. Fujimura T., Nakagawa S., Ohtani T., Ito Y., Aiba S., Inhibitory effect of the polyinosinic-polycytidylic acid/cationic liposome on the progression of murine B16F10 melanoma. The European Journal of Immunology 2006 36 12 3371 3380 10.1002/eji.200636053 2-s2.0-33845568917 (Pubitemid 44932738)
135. Al-Jamal W. T., Al-Jamal K. T., Bomans P. H., Frederik P. M., Kostarelos K., Functionalized-quantum-dot-liposome hybrids as multimodal nanopartides for cancer. Small 2008 4 9 1406 1415 10.1002/smll.200701043 2-s2.0-52649120918
136. Villares G. J., Zigler M., Wang H., Melnikova V. O., Wu H., Friedman R., Leslie M. C., Vivas-Mejia P. E., Lopez-Berestein G., Sood A. K., Bar-Eli M., Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. Cancer Research 2008 68 21 9078 9086 10.1158/0008-5472.CAN-08-2397 2-s2.0-55349098455
137. Inamdar G. S., Madhunapantula S. V., Robertson G. P., Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail. Biochemical Pharmacology 2010 80 5 624 637 10.1016/j.bcp.2010.04.029 2-s2.0-77954216113
138. Basu S., Harfouche R., Soni S., Chimote G., Mashelkar R. A., Sengupta S., Nanoparticle-mediated targeting of MAPK signaling predisposes tumor to chemotherapy. Proceedings of the National Academy of Sciences of the United States of America 2009 106 19 7957 7961 10.1073/pnas.0902857106 2-s2.0-66049083487
139. Yin D., Li Y., Lin H., Guo B., Du Y., Li X., Jia H., Zhao X., Tang J., Zhang L., Functional graphene oxide as a plasmid-based Stat3 siRNA carrier inhibits mouse malignant melanoma growth in vivo. Nanotechnology 2013 24 10 105102 10.1088/0957-4484/24/10/105102 2-s2.0-84874240212
140. Xie T., Huang F., Aldape K. D., Kang S., Liu M., Gershenwald J. E., Xie K., Sawaya R., Huang S., Activation of Stat3 in human melanoma promotes brain metastasis. Cancer Research 2006 66 6 3188 3196 10.1158/0008-5472.CAN-05-2674 2-s2.0-33645532055
141. Kong L., Gelbard A., Wei J., Reina-Ortiz C., Wang Y., Yang E. C., Hailemichael Y., Fokt I., Jayakumar A., Qiao W., Fuller G. N., Overwijk W. W., Priebe W., Heimberger A. B., Inhibition of p-STAT3 enhances IFN- α efficacy against metastatic melanoma in a murine model. Clinical Cancer Research 2010 16 9 2550 2561 10.1158/1078-0432.CCR-10-0279 2-s2.0-77951707745
142. Chen Y., Bathula S. R., Yang Q., Huang L., Targeted nanoparticles deliver siRNA to melanoma. The Journal of Investigative Dermatology 2010 130 12 2790 2798 10.1038/jid.2010.222 2-s2.0-78149467932
143. Tran M. A., Gowda R., Sharma A., Park E., Adair J., Kester M., Smith N. B., Robertson G. P., Targeting V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion development. Cancer Research 2008 68 18 7638 7649 10.1158/0008-5472.CAN-07-6614 2-s2.0-54849373400
144. Pizzimenti S., Ciamporcero E., Pettazzoni P., Osella-Abate S., Novelli M., Toaldo C., Husse M., Daga M., Minelli R., Bisazza A., Ferruti P., Ranucci E., Grazia Bernengo M., Dianzani C., Biasi F., Cavalli R., Barrera G., The inclusion complex of 4-hydroxynonenal with a polymeric derivative of β -cyclodextrin enhances the antitumoral efficacy of the aldehyde in several tumor cell lines and in a three-dimensional human melanoma model. Free Radical Biology and Medicine 2013 65 765 777 10.1016/j.freeradbiomed.2013.06.035 2-s2.0-84883464368
145. Benimetskaya L., Ayyanar K., Kornblum N., Castanotto D., Rossi J., Wu S., Lai J., Brown B. D., Popova N., Miller P., McMicken M., Chen Y., Stein C. A., Bcl-2 protein in 518A2 melanoma cells in vivo and in vitro. Clinical Cancer Research 2006 12 16 4940 4948 10.1158/1078-0432.CCR-06-1002 2-s2.0-33748349447 (Pubitemid 44338582)
146. Bedikian A. Y., Millward M., Pehamberger H., Conry R., Gore M., Trefzer U., Pavlick A. C., DeConti R., Hersh E. M., Hersey P., Kirkwood J. M., Haluska F. G., Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the oblimersen melanoma study group. Journal of Clinical Oncology 2006 24 29 4738 4745 10.1200/JCO.2006.06.0483 2-s2.0-33750600634 (Pubitemid 46630937)
147. Beloor J., Choi C. S., Nam H. Y., Park M., Kim S. H., Jackson A., Lee K. Y., Kim S. W., Kumar P., Lee S., Arginine-engrafted biodegradable polymer for the systemic delivery of therapeutic siRNA. Biomaterials 2012 33 5 1640 1650 10.1016/j.biomaterials.2011.11.008 2-s2.0-83355177991
148. Zhang Z., Tongchusak S., Mizukami Y., Kang Y. J., Ioji T., Touma M., Reinhold B., Keskin D. B., Reinherz E. L., Sasada T., Induction of anti-tumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen delivery. Biomaterials 2011 32 14 3666 3678 10.1016/j.biomaterials.2011.01.067 2-s2.0-79952106754
149. Perche F., Benvegnu T., Berchel M., Lebegue L., Pichon C., Jaffrès P., Midoux P., Enhancement of dendritic cells transfection in vivo and of vaccination against B16F10 melanoma with mannosylated histidylated lipopolyplexes loaded with tumor antigen messenger RNA. Nanomedicine: Nanotechnology, Biology, and Medicine 2011 7 4 445 453 10.1016/j.nano.2010.12. 010 2-s2.0-79960725328
150. Yao H., Ng S. S., Huo L., Chow B. K. C., Shen Z., Yang M., Sze J., Ko O., Li M., Yue A., Lu L., Bian X., Kung H., Lin M. C., Effective melanoma immunotherapy with interleukin-2 delivered by a novel polymeric nanoparticle. Molecular Cancer Therapeutics 2011 10 6 1082 1092 10.1158/1535-7163.MCT-10-0717 2-s2.0-79958749886
151. He H., Grignol V., Karpa V., Yen C., Laperle K., Zhang X., Jones N. B., Liang M. I., Lesinski G. B., Ho W. S. W., Carson W. E. III, Lee L. J., Use of a nanoporous biodegradable miniature device to regulate cytokine release for cancer treatment. Journal of Controlled Release 2011 151 3 239 245 10.1016/j.jconrel.2011.02.020 2-s2.0-79957495866
152. Speiser D. E., Schwarz K., Baumgaertner P., Manolova V., Devevre E., Sterry W., Walden P., Zippelius A., Conzett K. B., Senti G., Voelter V., Cerottini J., Guggisberg D., Willers J., Geldhof C., Romero P., Kündig T., Knuth A., Dummer R., Trefzer U., Bachmann M. F., Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients. Journal of Immunotherapy 2010 33 8 848 858 10.1097/CJI.0b013e3181f1d614 2-s2.0-77958051699
153. Camerin M., Magaraggia M., Soncin M., Jori G., Moreno M., Chambrier I., Cook M. J., Russell D. A., The in vivo efficacy of phthalocyanine-nanoparticle conjugates for the photodynamic therapy of amelanotic melanoma. European Journal of Cancer 2010 46 10 1910 1918 10.1016/j.ejca.2010.02.037 2-s2.0-77953286154
154. De Souza F. F., Dos Santos M. C., Dos Passos D. C., De Lima E. C., Guillo L. A., Curcumin associated magnetite nanoparticles inhibit in vitro melanoma cell growth. Journal of Nanoscience and Nanotechnology 2011 11 9 7603 7610 10.1166/jnn.2011.5124 2-s2.0-84856397381